Filing summary
Entity and period: The provided filing is Jupiter Wellness, Inc.’s Form 10-K for the fiscal year ended December 31, 2021—not a filing for BONK, INC. The filing reports full-year results, not a standalone fourth quarter. Confirm the issuer and filing before relying on this summary.
Business context
Jupiter Wellness develops and sells CBD-based skin-care and wellness products, while its wholly owned subsidiary SRM Entertainment supplies merchandise to theme parks. The CBD business includes marketed CaniSun products and development-stage therapeutic candidates, including JW-100 for eczema. SRM’s theme-park merchandise business generated most of 2021 revenue.
Financial performance
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $2.88 million | $1.07 million |
| Cost of sales | $2.34 million | $624,570 |
| Gross profit | $535,485 | $441,095 |
| Gross margin | 18.6% | 41.4% |
| Net loss | $28.10 million | $6.29 million |
| Basic and diluted loss per share | $1.69 | $0.86 |
| Cash used in operating activities | $7.57 million | $2.73 million |
| Cash used in investing activities | $13.15 million | $246,000 |
| Cash provided by financing activities | $28.21 million | $6.71 million |
At year-end, cash was $11.75 million, current assets were $16.28 million, current liabilities were $1.57 million, total liabilities were $2.27 million, and shareholders’ equity was $16.60 million. Current assets less current liabilities were approximately $14.71 million. The company reported $47,547 remaining on its SBA EIDL loan, $814,063 in lease liabilities, and no convertible-note balance. Cash increased from $4.26 million, primarily reflecting the 2021 public offering’s $28.32 million net proceeds.
Changes and unusual items
- Revenue rose 170% year over year, but gross margin fell from 41.4% to 18.6%. SRM contributed $2.69 million of 2021 revenue; Jupiter Wellness contributed $183,142. SRM revenue declined from $2.96 million in 2020 to $2.69 million in 2021, with COVID-related theme-park disruptions cited. The 2020 SRM segment figure covers only the period after its November 2020 acquisition, limiting comparability.
- Net loss widened substantially. Major 2021 items included a $10.0 million impairment of a secured note receivable, $9.39 million in stock-based compensation, and $1.74 million in interest expense. The filing also reports $1.08 million in research and development expense, up from $308,367.
- The company received $28.32 million in net proceeds from a July 2021 offering of 11.07 million common shares and warrants to purchase up to 11.61 million shares, creating substantial potential dilution.
- The audited statements report a 2021 net loss of $28.10 million; one MD&A table instead states $28.20 million. The filing does not reconcile this discrepancy.
Outlook, risks, and contingencies
- No quantified revenue or earnings guidance is provided. Management said year-end cash and working capital were sufficient to execute its business plan, following the offering. The company nevertheless reported substantial operating cash burn and an accumulated deficit of $35.37 million.
- In February 2022, Next Frontier Pharmaceuticals terminated the proposed acquisition agreement. The company reported that $11.2 million advanced under secured notes remained owed; the filing describes a $10.0 million December 2021 note and a separate January 2022 facility with a $1.0 million advance. A default notice was issued, and the company recorded a $10.0 million impairment in 2021. Recovery and the precise outstanding balance warrant review.
- Key risks include uncertain FDA and other regulation of CBD products, the need for clinical and regulatory progress before therapeutic products can be marketed for disease treatment, competition, dependence on third-party manufacturing, and COVID-related exposure in the theme-park business. The JW-100 eczema study showed 50% of participants achieved clear or almost clear skin with at least a two-grade improvement, versus 20% for CBD-only and 15% for placebo; the reported comparison was statistically significant (p=0.028). These early results do not establish FDA approval or commercial success.
- Management concluded internal control over financial reporting was ineffective as of year-end and disclosed plans to strengthen the control framework. The filing also discusses a pending lawsuit involving an unjust-enrichment counterclaim; trial was scheduled no earlier than November 2022. The company’s financial statements received an unqualified audit opinion, but the auditor did not attest to internal-control effectiveness.
- Subsequent to year-end, the company reported that Oppenheimer had repurchased 1,959,590 shares for $2.09 million by March 28, 2022. The filing gives no 2021 repurchases.
Investor verification priorities
- Verify the issuer: the supplied filing is for Jupiter Wellness, Inc. (Nasdaq: JUPW), not BONK, INC.
- Reconcile the $28.10 million audited net loss with the $28.20 million figure in MD&A, and confirm segment revenue and the acquisition-period basis for comparison.
- Review the enforceability, collateral, default status, and collectability of the Next Frontier notes, including the reported $11.2 million balance and $10.0 million impairment.
- Assess cash runway against operating cash use, planned clinical-trial commitments, and the company’s stated outlook; confirm whether the prior going-concern concern is fully resolved.
- Evaluate dilution from outstanding warrants and equity awards, and confirm the authorization and remaining scope of the post-year-end share repurchases.
- Track FDA requirements and clinical evidence for CBD products, and monitor the lawsuit and remediation of ineffective internal controls.